Avaliação do risco cardiovascular na síndrome metabólica

Abstract

It evaluates cardiovascular risk (CVR) in metabolic syndrome. There is no agreement about the best score to estimate the CVR in this population. The objective is to assess the coronary heart disease (CHD) risk in non-diabetic patients with MS using three different scores. Thirty nine subjects with MS were evaluated by the Framingham Risk Score (FRS), FRS modified by IV Diretriz Brasileira sobre Dislipidemias e Aterosclerose (mod-FRS) and by Prospective Cardiovascular Münster Study (PROCAM). All the subjects were submitted to clinical evaluation, electrocardiogram, echocardiogram, ambulatorial blood pressure monitorization, ankle brachial index (ABI) and dosages of glucose, creatinine, total cholesterol, HDLcholesterol, triglycerides and microalbuminúria. LDL-cholesterol was estimated by Friedwald’s formula. Mean age was 4421.0 years and most of individuals were female (31/39). Six subjects (15,4%) were smokers and 21 (53,8%) were hypertensive. Low HDL-cholesterol was detected in 35 (89,7%) individuals and high triglycerides, total cholesterol and LDL-cholesterol levels were observed in 28 (71,8%), 19 (48,7%) e 15 (38,5%) individuals, respectively. Microalbuminuria was diagnosed in 23 (59%) subjects, left ventricular hypertrophy in three (7,7%) and peripheral vascular disease in five (12,8%). Based in the FRS the CHD risk in 10 years was considered low in 35 (89,7%) individuals and intermediate in four (10,3%), with no patient in high risk group. On the other hand, the mod-FRS detected five (12,8%) subjects in low risk, 30 (76,9%) in the intermediate and four (10,3%) individuals in the high risk group. According to PROCAM 29 (74,4%) individuals were in low risk, seven (17,9%) in the intermediate and three (7,7%) in high risk group. In non-diabetic subjects with MS the FRS underestimates the CHD risk, whereas the mod-FRS and alternatively, the PROCAM seem to be more accurate in estimating this risk.